News

A substantial portion of antiretroviral-naïve patients are infected with transmitted drug-resistant HIV with one or more drug-resistant mutations, and they are much more likely to experience treatment failure, according to research published in The Lancet Infectious Diseases.

Patients with psoriatic arthritis undergoing their first treatment with tumor necrosis factor-? inhibitor showed a high adherence to therapy and a good response, according to a recent Danish study published in Arthritis & Rheumatism.

Many patients, especially those with limited literacy, do not consolidate prescription medication regimens efficiently, which could lead to nonadherence, according to a recent study in the Archives of Internal Medicine.

The willingness of the elderly to take medication for primary cardiovascular disease prevention is relatively insensitive to its benefit but highly sensitive to its adverse effects, according to a recent study published in the Archives of Internal Medicine.

The Indiana Health Information Exchange (IHIE) announced that its Quality Health First Program has enrolled more than 1,500 physicians in more than 50 communities

CareFirst, Inc., Owings Mills, Md., is launching a new Primary Care Medical Home (PCMH) program that takes aim at the chronically ill.

Open Health Market, a request for proposal (RFP) generation tool designed to allow employers of self-funded health plans to solicit and compare proposals directly from medical providers, is ready to launch.

XLHealth, a Baltimore-based provider of health plan solutions for Medicare beneficiaries with special needs, announced the enrollment of its 100,000th member, and it sees room for more growth despite expected Medicare Advantage cuts

FDA has approved a change to the prescribing information for ambrisentan 5-mg and 10-mg tablets (Letairis, Gilead Sciences) once-daily treatment to improve exercise ability and delay clinical worsening in patients with pulmonary arterial hypertension (PAH, WHO Group 1) and predominantly WHO Functional Class II-III symptoms.

FDA recently announced its plans to remove certain unapproved prescription medicines used to treat cough, cold, and allergy symptoms.

Children aged 6 to 23 months who receive trivalent inactivated flu vaccine concurrently with the 13-valent pneumococcal conjugate vaccine are at increased risk of febrile seizures, according to researchers at the Centers for Disease Control and Prevention in Atlanta and Harvard Medical School in Boston.

The angiogenesis inhibitor bevacizumab, used with chemotherapy or biological therapy, carries an increased risk of treatment-related death in cancer patients compared with chemotherapy alone, a new study shows.

The anticancer drug bevacizumab could help prevent babies with retinopathy of prematurity from becoming blind, reports a new study from the University of Texas Health Science Center at Houston Medical School.

FDA has updated the pregnancy section of drug labels for the entire class of antipsychotic medications to provide more information about the potential risk of extrapyramidal signs and withdrawal symptoms in newborns whose mothers take antipsychotics during the third trimester of pregnancy.

FDA's Pulmonary-Allergy Drugs Advisory Committee voted to approve Novartis' QAB149 (indacaterol) 75 µg as a once-daily long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema, PR Newswire reported.

The American College of Physicians recently issued 3 recommendations for use of intensive insulin therapy for the management of glycemic control in hospitalized patients.

FDA approved the first-and-only selective phosphodiesterase type 4 inhibitor roflumilast (Daliresp, Forest Pharmaceuticals), once-daily oral tablet to decrease the frequency of exacerbations or worsening of symptoms from severe chronic obstructive pulmonary disease.

FDA approved the use of once-daily guanfacine (Intuniv, Shire) extended-release tablets as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder in children and adolescents aged 6 to 17 years as part of a total treatment program.

FDA issued a complete response letter to EMD Serono, an affiliate of Merck KGaA, requesting additional information on cladribine (Movectro), a drug intended for the treatment of relapsing-remitting multiple sclerosis.

A recent recall of generic warfarin tablets was expanded to include 6 other drug products prepared on the same packaging line.

In mid February, US Marshals acting on a request of FDA seized all lots of Auralgan Otic Solution from Integrated Commercialization Solutions in Brooks, Ky.

Agents in late-stage development for the treatment of rare cancers.

Recent FDA action (through, February 2011) related to Contrave, rabeprazole sodium extended-release capsules, Avodart, Mu Delta, Carfilzomib, Vascugel, INX-0818, vosaroxin, Acurox, fidaxomicin, melanoma cancer vaccine, NSI-566RSC, Regorafenib.

New formulation: Fentanyl sublingual tablets were approved by FDA to manage breakthrough pain in patients aged ?18 years who are already receiving and tolerant to opioids for their underlying persistent cancer pain.

Generic drugs approved by FDA (through February 2011): Galantamine hydrobromide

The active drug safety surveillance system being established by FDA promises to do more than obtain timely adverse event information on marketed medicines.

New molecular entity: Vilazodone hydrochloride tablets were approved by FDA on January 21, 2011, for the treatment of major depressive disorder in adults.

Recent FDA Approvals (through February 2011) related to Edarbi, Gralise, Rituxan, Menveo, Makena, Corifact, Epicyn HydroGel